ArticleJTO clinical and research reports2022

BMS-986012, an Anti-Fucosyl-GM1 Monoclonal Antibody as Monotherapy or in Combination With Nivolumab in Relapsed/Refractory SCLC: Results From a First-in-Human Phase 1/2 Study.

Quincy Chu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.